Median Technologies Submits U.S. Application for 510(k) Clearance of eyonis® LCS

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced it has filed an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of eyonis® LCS, its AI/ML tech-based SaMD for computer aided detection and diagnosis (CADe/CADx) in lung cancer screening.

The submission is based on positive data from the two pivotal studies of eyonis® LCS, REALITY and RELIVE, both of which met their primary endpoints. This data demonstrated that eyonis® LCS provides robust diagnostic performance for early detection and characterization of lung nodules in high-risk lung cancer populations, with significant potential to impact patients’ clinical outcomes. Additionally, Median’s eyonis® LCS SaMD confirmed safety and efficacy in RELIVE, the second and last pivotal study.

“eyonis® LCS’ FDA filing is a major milestone for Median and a testament to our R&D and clinical programs’ strength,” said Fredrik Brag, CEO and Founder of Median Technologies. “RELIVE and REALITY pivotal studies met their primary endpoints and confirmed the device’s safety and efficacy. This shows that eyonis® LCS has the potential to be a game-changer in lung cancer screening. By providing early detection and characterization at scale, eyonis® LCS can significantly improve high-risk patient outcomes. Based on average observed review regulatory timeframes, we would expect an eyonis® LCS’ clearance in the U.S. in Q3 this year.”
Results from REALITY released in August 2024, showed that eyonis® LCS can accurately detect and characterize lung nodules, with exceptional results of an area under the curve (AUC) value of 0.904 versus the minimum value set as a primary endpoint for REALITY of an AUC of 0.80. Results from RELIVE released in March 2025, showed that radiologists aided by eyonis® LCS achieved statistically significant improved performance over radiologists alone (p=0.027) and can thus improve clinicians’ diagnostic accuracy in analyzing low dose computed tomography (LDCT) lung cancer screening scans. In addition, importantly, the Company believes that eyonis® LCS can increase efficiency of LDCT scans analyses, so that healthcare professionals can process many more patients through lung cancer screening with greater confidence in diagnostic accuracy.

Lung cancer screening is recommended by the U.S. Preventive Services Task Force (USPSTF) in adults aged 50 to 80 years who have a 20 pack-year smoking history. The market opportunity includes a population of 14.5 million people in the U.S. alone, currently eligible for a lung cancer screening exam, with an existing potential reimbursement of $650 per exam with a SaMD postprocessing for characterization of malignant vs benign nodules. This represents a total addressable annual market of over $10bn. The eligible U.S. patient number is expected to rise in the coming years, driven by planned broadening of the eligibility criteria. Similarly, new lung screening program deployments are planned in Europe and Asia.

In the US alone, the direct medical costs of cancer patients care were estimated to be nearly $230 billion in 2023[1]. The vast majority of cancer care costs are incurred in treating advanced cancer patients, versus preventive care such as screening that save patients’ lives.